UNLABELLED: Aristolochic acid I (AAI) is a natural plant alkaloid causing aristolochic acid nephropathy, Balkan endemic nephropathy and their associated urothelial malignancies. One of the most efficient enzymes reductively activating AAI to species forming AAI-DNA adducts is cytosolic NAD(P)H: quinone oxidoreductase 1. AAI is also either reductively activated or oxidatively detoxified to 8-hydroxyaristolochic acid (AAIa) by microsomal cytochrome P450 (CYP) 1A1 and 1A2. Here, we investigated which of these two opposing CYP1A1/2-catalyzed reactions prevails in AAI metabolism in vivo. The formation of AAI-DNA adducts was analyzed in liver, kidney and lung of rats treated with AAI, Sudan I, a potent inducer of CYP1A1/2, or AAI after pretreatment with Sudan I. Compared to rats treated with AAI alone, levels of AAI-DNA adducts determined by the (32)P-postlabeling method were lower in liver, kidney and lung of rats treated with AAI after Sudan I. The induction of CYP1A1/2 by Sudan I increased AAI detoxification to its O-demethylated metabolite AAIa, thereby reducing the actual amount of AAI available for reductive activation. This subsequently resulted in lower AAI-DNA adduct levels in the rat in vivo. Our results demonstrate that CYP1A1/2-mediated oxidative detoxification of AAI is the predominant role of these enzymes in rats in vivo, thereby suppressing levels of AAI-DNA adducts.

Analytical and Environmental Sciences Division MRC PHE Centre for Environment and Health King's College London London United Kingdom

Department of Biochemistry Faculty of Science Charles University Prague Prague Czech Republic

Division of Radiopharmaceutical Chemistry German Cancer Research Center Heidelberg Germany

See more in PubMed

Arlt V.M., Ferluga D., Stiborova M., Pfohl-Leszkowicz A., Vukelic M., Ceovic S., Schmeiser H.H., Cosyns J.P. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int. J. Cancer. 2002;101:500–502. PubMed

Arlt V.M., Stiborova M., Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis. 2002;17:265–277. PubMed

Arlt V.M., Stiborova M., vom Brocke J., Simoes M.L., Lord G.M., Nortier J.L., Hollstein M., Phillips D.H., Schmeiser H.H. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis. 2007;28:2253–2261. PubMed

Arlt V.M., Levova K., Barta F., Shi Z., Evans J.D., Frei E., Schmeiser H.H., Nebert D.W., Phillips D.H., Stiborova M. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/- Cyp1a2-/-, and Cyp1a1/1a2-/- mice. Chem. Res. Toxicol. 2011;24:1710–1719. PubMed

Arlt V.M., Henderson C.J., Wolf C.R., Stiborova M., Phillips D.H. The Hepatic Reductase Null (HRN™) and Reductase Conditional Null (RCN) mouse models as suitable tools to study metabolism, toxicity and carcinogenicity of environmental pollutants. Toxicol. Res. 2015;4:548–562.

Burke M.D., Thompson S., Weaver R.J., Wolf C.R., Mayer R.T. Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem. Pharmacol. 1994;48:923–936. PubMed

Chan W., Cu L., Xu G., Cai Z. Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. Rapid. Commun. Mass Spectrom. 2006;20:1755–1760. PubMed

Chen M., Gong L., Qi X., Xing G., Luan Y., Wu Y., Xiao Y., Yao J., Li Y., Xue X., Pan G., Ren J. Inhibition of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its nephrotoxicity. Toxicol. Sci. 2011;122:288–296. PubMed

Gökmen M.R., Cosyns J.P., Arlt V.M., Stiborová M., Phillips D.H., Schmeiser H.H., Simmonds M.S.J., Look H.T., Vanherweghem J.L., Nortier J.L., Lord G.M. The epidemiology: diagnosis and management of aristolochic acid nephropathy: a narrative review. Ann. Intern. Med. 2013;158:469–477. PubMed

Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelic M., Jelakovic B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U. S. A. 2007;104:12129–12134. PubMed PMC

Hoang M.L., Chen C.H., Sidorenko V.S., He J., Dickman K.G., Yun B.H., Moriya M., Niknafs N., Douville C., Karchin R., Turesky R.J., Pu Y.S., Vogelstein B., Papadopoulos N., Grollman A.P., Kinzler K.W., Rosenquist T.A. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci. Transl. Med. 2013;5:197ra102. PubMed PMC

IARC IARC Monogr. Eval. Carcinog. Risk Hum. 2012;100A

Jerabek P., Martinek V., Stiborova M. Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1. Neuro Endocrinol. Lett. 2012;33(3):25–32. PubMed

Kobayashi K., Urashima K., Shimada N., Chiba K. Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat. Biochem. Pharmacol. 2002;63:889–896. PubMed

Kucab J.E., Phillips D.H., Arlt V.M. Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock-in (Hupki) mouse model. FEBS J. 2010;277:2567–2583. PubMed

Levová K., Mizerová M., Kotrbová V., Šulc M., Henderson C.J., Wolf C.R., Philips D.H., Frei E., Schmeiser H.H., Mareš J., Arlt V.M., Stiborová M. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. Toxicol. Sci. 2011;121:43–56. PubMed

Levová K., Moserova M., Nebert D.W., Phillips D.H., Frei E., Schmeiser H.H., Arlt V.M., Stiborova M. NAD(P)H:quinone oxidoreductase expression in Cyp1a-knockout and CYP1A-humanized mouse lines and its effect on bioactivation of the carcinogen aristolochic acid I. Toxicol. Appl. Pharmacol. 2012;265:360–367. PubMed

Lord G.M., Hollstein M., Arlt V.M., Roufosse C., Pusey C.D., Cook T., Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 2004;43:e11–e17. PubMed

Martinek V., Kubickova B., Arlt V.M., Frei E., Schmeiser H.H., Hudeček J., Stiborova M. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. Neuro Endocrinol. Lett. 2011;32(1):57–70. PubMed

Nedelcheva V., Gut I. P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica. 1994;24:1151–1175. PubMed

Nedelko T., Arlt V.M., Phillips D.H., Hollstein M. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int. J. Cancer. 2009;124:987–990. PubMed

Nik-Zainal S., Kucab J.E., Morganella S., Glodzik D., Alexandrov L.B., Arlt V.M., Weninger A., Hollstein M., Stratton M.R., Phillips D.H. The genome as a record of environmental exposure. Mutagenesis. 2015;30:763–770. PubMed PMC

Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., Vanherweghem J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi) N. Engl. J. Med. 2000;342:1686–1692. PubMed

Pfau W., Schmeiser H.H., Wiessler M. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis. 1990;11:1627–1633. PubMed

Poon S.L., Pang S.T., McPherson J.R., Yu W., Huang K.K., Guan P., Weng W.H., Siew E.Y., Liu Y., Heng H.L., Chong S.C., Gan A., Tay S.T., Lim W.K., Cutcutache I., Huang D., Ler L.D., Nairismägi M.L., Lee M.H., Chang Y.H., Yu K.J., Chan-On W., Li B.K., Yuan Y.F., Qian C.N., Ng K.F., Wu C.F., Hsu C.L., Bunte R.M., Stratton M.R., Futreal P.A., Sung W.K., Chuang C.K., Ong C.K., Rozen S.G., Tan P., Teh B.T. Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. Sci. Transl. Med. 2013;5:197ra101. PubMed

Refat N.A., Ibrahim Z.S., Moustafa G.G., Sakamoto K.Q., Ishizuka M., Fujita S. The induction of cytochrome P450 1A1 by Sudan dyes. J. Biochem. Mol. Toxicol. 2008;22:77–84. PubMed

Rosenquist T.A., Einolf H.J., Dickman K.G., Wang L., Smith A., Grollman A.P. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab. Disp. 2010;38:761–768. PubMed PMC

Schmeiser H.H., Bieler C.A., Wiessler M., van Ypersele de Strihou C., Cosyns J.P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 1996;56:2025–2028. PubMed

Schmeiser H.H., Frei E., Wiessler M., Stiborová M. Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis. 1997;18:1055–1062. PubMed

Schmeiser H.H., Stiborová M., Arlt V.M. Chemical and molecular basis of the carcinogenicity of Aristolochia plants. Curr. Opin. Drug Discov. Devel. 2009;12:141–148. PubMed

Schmeiser H.H., Kucab J.E., Arlt V.M., Phillips D.H., Hollstein M., Gluhovschi G., Gluhovschi C., Modilca M., Daminescu L., Petrica L., Velciov S. Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ. Mol. Mutagen. 2012;53:636–641. PubMed

Schmeiser H.H., Stiborova M., Arlt V.M. 32P-postlabeling analysis of DNA adducts. Methods Mol. Biol. 2013;1044:389–401. PubMed

Schmeiser H.H., Nortier J., L, Singh R., Gamboa da Costa G., Sennesael J., Cassuto-Viguier E., Ambrosetti D., Rorive S., Pozdzik A., Phillips D.H., Stiborova M., Arlt V.M. Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. Int. J. Cancer. 2014;135:562–567. PubMed

Shibutani S., Bonala R.R., Rosenquist T., Rieger R., Suzuki N., Johnson F., Miller F., Grollman A.P. Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int. J. Cancer. 2010;127:1021–1027. PubMed PMC

Sistkova J., Hudecek J., Hodek P., Frei E., Schmeiser H.H., Stiborova M. Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol. Lett. 2008;29:733–737. PubMed

Stiborová M., Asfaw B., Anzenbacher P., Hodek P. A new way to carcinogenicity of azo dyes The benzenediazonium ion formed from a non-aminoazo dye, 1-phenylazo-2- hydroxynaphthalene (Sudan I) by microsomal enzymes binds to deoxyguanosine residues of DNA. Cancer Lett. 1988;40:327–333. PubMed

Stiborová M., Fernando R.C., Schmeiser H.H., Frei E., Pfau W., Wiessler M. Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis. 1994;15:1187–1192. PubMed

Stiborová M., Frei E., Wiessler M., Schmeiser H.H. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol. 2001;14:1128–1137. PubMed

Stiborová M., Frei E., Sopko B., Wiessler M., Schmeiser H.H. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis. 2002;23:617–625. PubMed

Stiborová M., Martínek V., Rýdlová H., Hodek P., Frei E. Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. Cancer Res. 2002;62:5678–5684. PubMed

Stiborová M., Frei E., Sopko B., Sopková K., Marková V., Laňková M., Kumstýřová T., Wiessler M., Schmeiser H.H. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis. 2003;24:1695–1703. PubMed

Stiborová M., Frei E., Hodek P., Wiessler M., Schmeiser H.H. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:CYP reductase and prostaglandin H synthase mediate the formation of aristolochic acid DNA-adducts found in patients with urothelial cancer. Int. J. Cancer. 2005;113:189–197. PubMed

Stiborová M., Sopko B., Hodek P., Frei E., Schmeiser H.H., Hudeček J. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. Cancer Lett. 2005;229:193–204. PubMed

Stiborová M., Martínek V., Rýdlová H., Koblas T., Hodek P. Expression of cytochrome P450 1A1 and its contribution to oxidation of a potential human carcinogen 1-phenylazo-2-naphthol (Sudan I) in human livers. Cancer Lett. 2005;220:145–154. PubMed

Stiborová M., Dračínská H., Hájková J., Kadeřábková P., Frei E., Schmeiser H.H., Souček P., Phillips D.H., Arlt V.M. The environmental pollutant and carcinogen 3-nitrobenzanthrone and its human metabolite 3-aminobenzanthrone are potent inducers of rat hepatic cytochromes P450 1A1 and −1A2 and NAD(P)H:quinone oxidoreductase. Drug Metab. Disp. 2006;34:1398–1405. PubMed

Stiborová M., Frei E., Arlt V.M., Schmeiser H.H. Metabolic activation of carcinogenic aristolochic acid: a risk factor for Balkan endemic nephropathy Mutat. Res. Rev. Mutat. Res. 2008;658:55–67. PubMed

Stiborová M., Frei E., Schmeiser H.H. Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int. 2008;73:1209–1211. PubMed

Stiborová M., Mareš J., Frei E., Arlt V.M., Martínek V., Schmeiser H.H. The human carcinogen aristolochic acid I is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. Environ. Mol. Mutagen. 2011;52:448–459. PubMed

Stiborová M., Mareš J., Levová K., Pavlíčková J., Bárta F., Hodek P., Frei E., Schmeiser H.H. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver. Neuro Endocrinol. Lett. 2011;32(1):121–130. PubMed

Stiborová M., Levová K., Bárta F., Shi Z., Frei E., Schmeiser H.H., Nebert D.W., Phillips D.H., Arlt V.M. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. Toxicol. Sci. 2012;125:345–358. PubMed PMC

Stiborová M., Dračínská H., Martínek V., Svášková D., Hodek P., Milichovský J., Hejduková Ž, Brotánek J., Schmeiser H.H., Frei E. Induced expression of cytochrome P450 1A and NAD(P)H:quinone oxidoreductase determined at mRNA, protein and enzyme activity levels in rats exposed to the carcinogenic azo dye 1-phenylazo-2-naphthol (Sudan I) Chem. Res. Toxicol. 2013;26:290–299. PubMed

Stiborová M., Martínek V., Frei E., Arlt V.M., Schmeiser H.H. Enzymes metabolizing aristolochic acid and their contribution to the development of Aristolochic acid nephropathy and urothelial cancer. Curr. Drug Metab. 2013;14:695–705. PubMed

Stiborová M., Frei E., Arlt V.M., Schmeiser H.H. Knock-out and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica. 2014;44:135–145. PubMed

Stiborová M., Frei E., Schmeiser H.H., Arlt V.M., Martínek V. 2014. Mechanisms of enzyme-catalyzed reduction of two carcinogenic nitro-aromatics: 3-nitrobenzanthrone and aristolochic acid I: experimental and theoretical approaches. Int. J. Mol. Sci. 2014;15:10271–10295. PubMed PMC

Stiborová M., Levová K., Bárta F., Šulc M., Frei E., Arlt V.M., Schmeiser H.H. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis. 2014;29:189–200. PubMed

Stiborová M., Bárta F., Levová K., Hodek P., Frei E., Arlt V.M., Schmeiser H.H. The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats. Arch. Toxicol. 2015;89:2141–2158. PubMed

Stiborová M., Bárta F., Levová K., Hodek P., Schmeiser H.H., Arlt V.M., Martínek V. A mechanism of O-demethylation of aristolochic acid I by cytochromes P450 and their contributions to this reaction in human and rat livers: experimental and theoretical approaches. Int. J. Mol. Sci. 2015;16:27561–27562. PubMed PMC

Vanherweghem J.L., Depierreux M., Tielemans C., Abramowicz D., Dratwa M., Jadoul M., Richard C., Vandervelde D., Verbeelen D., Vanhaelen-Fastre R., Vanhaelen M. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341:387–391. PubMed

Večeřa R., Zachařová A., Orolin J., Strojil J., Skottová N., Anzenbacher P. Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat. Biopharm. Drug Dispos. 2011;32:482–487. PubMed

Wiechelman K.J., Braun R.D., Fitzpatrick J.D. Investigation of the bicinchoninic acid protein assay: identified cation of the groups responsible for color formation. Anal. Biochem. 1988;175:231–237. PubMed

Xiao Y., Ge M., Xue X., Wang C., Wang H., Wu X., Li L., Liu L., Qi X., Zhang Y., Li Y., Luo H., Xie T., Gu J., Ren J. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 2008;73:1231–1239. PubMed

Xue X., Xiao Y., Zhu H., Wang H., Liu Y., Xie T., Ren J. Induction of P450 1A by 3-methylcholanthrene protects mice from aristolochic acid-I-induced acute renal injury. Nephrol. Dial. Transplant. 2008;23:3074–3081. PubMed

Yamazaki H., Shimizu M., Nagashima T., Minoshima M., Murayama N. Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. Drug Metab. Dispos. 2006;34:1803–1805. PubMed

Yun B.H., Rosenquist T.A., Sidorenko V., Iden C.R., Chen C.H., Pu Y.S., Bonala R., Johnson F., Dickman K.G., Grollman A.P., Turesky R.J. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem. Res. Toxicol. 2012;25:1119–1131. PubMed PMC

Zachařová A., Siller M., Spičáková A., Anzenbacherová E., Skottová N., Anzenbacher P., Večeřa R. Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. Xenobiotica. 2012;42:731–736. PubMed

Co-Exposure to Aristolochic Acids I and II Increases DNA Adduct Formation Responsible for Aristolochic Acid I-Mediated Carcinogenicity in Rats

DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer

Comparison of the oxidation of carcinogenic aristolochic acid I and II by microsomal cytochromes P450 in vitro: experimental and theoretical approaches

Balkan endemic nephropathy: an update on its aetiology